Monitoring for Adverse Events Sample Clauses
The "Monitoring for Adverse Events" clause establishes the requirement for ongoing observation and reporting of any negative or unintended effects that may arise during the course of a project, clinical trial, or product use. Typically, this clause outlines the responsibilities of parties to detect, document, and communicate adverse events promptly, often specifying timelines and reporting procedures. Its core practical function is to ensure participant safety and regulatory compliance by enabling early identification and management of risks associated with the activity or product.
Monitoring for Adverse Events. At each visit, after the subject has had the opportunity to spontaneously mention any problems, the Investigator should inquire about AEs by asking the standard questions: • “Have you had any health problems since your last study visit?” • “Have there been any changes in the medicines you take since your last study visit?” Additionally, changes in any protocol-specific parameters and/or questionnaires evaluated during the study are to be reviewed by the Investigator. Any untoward (unfavorable and unintended) change in a protocol-specific parameter or questionnaire response that is clinically relevant, in the opinion of the Investigator, is to be reported as an AE. These clinically relevant changes will be reported regardless of causality.
Monitoring for Adverse Events. At each visit, after the subject has had the opportunity to spontaneously mention any problems, the Investigator should inquire about AEs by asking the standard questions: • “Have you had any health problems since your last study visit?” • “Have there been any changes in the medicines you take since your last study visit?”